Aragen Secures $100M Investment from Quadria Capital for Expansion

• Aragen announces a $100M investment from Quadria Capital, valuing the company at $1.4 billion.

• Funding will drive infrastructure and capability expansion to meet increasing demand in the pharmaceutical outsourcing market.

Aragen, a Contract Research, Development and Manufacturing Organisation (CRDMO), has secured a $100 million investment from Quadria Capital, an Asia-focused private equity fund specialising in healthcare. The deal, which values Aragen at approximately $1.4 billion, includes a combination of fresh capital and a minor sale of existing shares by current investors.

The investment aims to enhance Aragen’s infrastructure and service capabilities to meet growing outsourcing needs from pharmaceutical innovators in the United States and Europe. “This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market,” said Manni Kantipudi, CEO of Aragen Life Sciences.

Quadria Capital now joins Goldman Sachs as a strategic investor in Aragen. The company, known for its integrated services spanning discovery to commercial manufacturing for small molecules and biologics, serves over 400 clients globally, including 15 of the world’s top 20 pharmaceutical companies.

The announcement comes ahead of JPM Week 2025, during which Aragen is expected to solidify additional partnerships. Aragen’s growth aligns with industry trends as Western pharmaceutical firms diversify supply chains to mitigate global disruptions.

Quadria’s Managing Partner and Co-Founder, Dr. Amit Varma, highlighted the strategic alignment, stating, “The pharmaceutical outsourcing sector presents compelling growth opportunities. Aragen’s impressive track record and commitment to innovation make it an ideal partner for global pharmaceutical companies.”